Sanara Medtech Inc (SMTI) 주가 예측

Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.